{{Drugbox
| IUPAC_name        = ''N''-[(1''R'',2''R'')-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide
| image             = Eliglustat.svg
| tradename         = Cerdelga
| CAS_number        = 491833-29-5
| ATC_prefix        = A16
| ATC_suffix        = AX10
| PubChem           = 23652731
| DrugBank          = 
| ChemSpiderID      = 28475348
| ChEBI_Ref = {{ebicite|correct|EBI}} 
| ChEBI = 82752
| KEGG = D09893
| C=23 | H=36 | N=2 | O=4
| molecular_weight  = 404.543 g/mol
| smiles            = CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O
| StdInChI          = 1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1
| StdInChIKey       = FJZZPCZKBUKGGU-AUSIDOKSSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  Rx-only <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

'''Eliglustat''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]];<ref>{{citation |url=https://download.ama-assn.org/resources/doc/usan/x-pub/eligustat.pdf |format=PDF |publisher=AMA |title=Eligustat}} By subscription only</ref> trade name '''Cerdelga''') is a treatment for [[Gaucher's disease]] developed by [[Genzyme|Genzyme Corp]] that was approved by the FDA August 2014.<ref>{{citation |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm410585.htm |title=FDA approves new drug to treat a form of Gaucher disease |date=19 August 2015 |accessdate=18 July 2015 |publisher=U.S. Food and Drug Administration }}</ref> Commonly used as the [[tartrate]] [[salt (chemistry)|salt]], the compound is believed to work by inhibition of [[Ceramide glucosyltransferase|glucosylceramide synthase]].<ref>{{cite journal|last1=Lee|first1=L.|last2=Abe|first2=A.|last3=Shayman|first3=J. A.|title=Improved Inhibitors of Glucosylceramide Synthase|journal=Journal of Biological Chemistry|date=21 May 1999|volume=274|issue=21|pages=14662–14669|doi=10.1074/jbc.274.21.14662}}</ref><ref>{{cite journal|last1=Shayman|first1=JA|title=Eliglustat Tartrate: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.|journal=Drugs of the future|date=1 August 2010|volume=35|issue=8|pages=613–620|pmid=22563139|doi=10.1358/dof.2010.035.08.1505566|pmc=3340614}}<!--|accessdate=21 August 2014--></ref> According to an article in ''[[Journal of the American Medical Association]]'' the oral [[substrate reduction therapy]] resulted in "significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count" in untreated adults with Gaucher disease Type 1.<ref name="AMA_2015">{{citation |title=Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: The ENGAGE Randomized Clinical Trial |journal=Journal of the American Medical Association |date=17 February 2015 |author=Pramod K. Mistry |author2=Elena Lukina |author3=Hadhami Ben Turkia |author4=Dominick Amato |author5=Hagit Baris |author6=Majed Dasouki |author7=Marwan Ghosn |author8=Atul Mehta |author9=Seymour Packman |author10=Gregory Pastores |author11=Milan Petakov |author12=Sarit Assouline |author13=Manisha Balwani |author14=Sumita Danda |author15=Evgueniy Hadjiev |author16=Andres Ortega |author17=Suma Shankar |author18=Maria Helena Solano |author19=Leorah Ross |author20=Jennifer Angell |author21=M. Judith Peterschmitt |volume=313 |number=7 |pages=695–706 |doi=10.1001/jama.2015.459 |pmid=25688781 |pmc=4962880}}</ref>

==Cost==

In 2014, the annual cost of eliglustat taken orally twice a day was $310,250. Genzyme's flagship [[imiglucerase]] (brand name ''Cerezyme'') cost about $300,000 for the infusions if taken twice a month.<ref name="Weisman_2014">{{citation |title=New Genzyme pill will cost patients $310,250 a year |publisher=The Boston Globe |url=https://www.bostonglobe.com/business/2014/09/02/new-genzyme-pill-treat-rare-gaucher-disease-will-cost-patients-year/5thkIb587nKi7zRAb9GgxM/story.html |author=Robert Weisman |date=2 September 2014 |accessdate=18 July 2015}}</ref> Manufacturing costs for eliglustat are slightly lower than for imiglucerase. Genzyme's maintains higher prices for [[orphan drugs]]—most often paid for by insurers—in order to remain financially sustainable.<ref name="Weisman_2014" />

==References==
{{Reflist}}

{{Other alimentary tract and metabolism products}}

[[Category:Transferase inhibitors]]
[[Category:Carboxamides]]


{{gastrointestinal-drug-stub}}